The Journal of Practical Medicine >

2026 , Vol. 42 >Issue 15: 2722 - 2729

DOI: https://doi.org/10.3969/j.issn.1006-5725.2026.15.007

Oncology: Diagnosis, Treatment and Prevention

Immunosuppressive effects and targeted therapeutic strategies of platelet-derived PD-L1 in hematogenous tumor metastasis

  • Jiacheng JIANG ,
  • Jie MA ,
  • Wei ZHU
Expand
  • 1.School of Clinical Medicine and Medical Laboratory Science，Jiangsu University，Zhenjiang 212013，Jiangsu，China
    3.Department of Laboratory Medicine，the People's Hospital of Danyang，Danyang 212300，Jiangsu，China
    2.School of Basic Medicine and Public Health，Jiangsu University，Zhenjiang 212013，Jiangsu，China

Received date: 2026-05-28

  Revised date: 2026-06-24

  Accepted date: 2026-06-26

  Online published: 2026-08-13

Fold

Abstract

Platelets are the second most abundant cellular component in blood after erythrocytes and have traditionally been recognized primarily for their roles in hemostasis and thrombosis. The expression of programmed death-ligand 1 （PD-L1） on the platelet surface enables direct inhibition of T cell function. Moreover， platelets can form a physical barrier by surrounding circulating tumor cells （CTCs）， thereby amplifying immunosuppressive signals synergistically and establishing a mobile immune barrier during hematogenous tumor metastasis. This review systematically summarizes the origin and regulatory mechanisms of platelet PD-L1 （pPD-L1） and proposes a triple-inhibition model of immune evasion mediated by pPD-L1. Furthermore， it highlights the critical role of pPD-L1 as a liquid biopsy biomarker in reversing resistance to immune checkpoint inhibitors （ICIs） and suppressing hematogenous tumor metastasis， providing a theoretical basis for precision therapies targeting pPD-L1.

Key words： platelets; programmed death-ligand 1; immune evasion; hematogenous metastasis; immune checkpoint inhibitors （ICIs）; antiplatelet therapy

Cite this article

Jiacheng JIANG , Jie MA , Wei ZHU . Immunosuppressive effects and targeted therapeutic strategies of platelet-derived PD-L1 in hematogenous tumor metastasis[J]. The Journal of Practical Medicine, 2026 , 42(15) : 2722 -2729 . DOI: 10.3969/j.issn.1006-5725.2026.15.007

References

[1] LI S， LU Z， WU S， et al. The dynamic role of platelets in cancer progression and their therapeutic implications［J］. Nat Rev Cancer， 2024， 24（1）：72-87. doi： 10.1038/s41568-023-00639-6 .
[2] 何嘉豪， 江倩， 刘春丽.血栓弹力图与传统凝血功能检测的相关性与一致性分析［J］. 实用医学杂志， 2022， 38（5）： 606-610. doi： 10.3969/j.issn.1006-5725.2022.05.016 .
[3] 张旺发，李明欣，陈荣鹏，等. Ⅳ期结直肠癌化疗前血小板参数与化疗敏感性及预后的关系［J］.实用医学杂志，2021，37（20）：2608-2613. doi： 10.3969/j.issn.1006-5725.2021.20.008 .
[4] CHAMBERS A F， NAUMOV G N， VARGHESE H J， et al. Critical steps in hematogenous metastasis： an overview［J］. Surg Oncol Clin N Am， 2001，10（2）：243-255. doi： 10.1016/s1055-3207（18）30063-2 .
[5] LEE D Y， IM E， YOON D， LEE Y S， et al. Pivotal role of PD-1/PD-L1 immune checkpoints in immune escape and cancer progression： Their interplay with platelets and FOXP3+Tregs related molecules， clinical implications and combinational potential with phytochemicals［J］. Semin Cancer Biol， 2022， 86（3）：1033-1057. doi： 10.1016/j.semcancer.2020.12.001 .
[6] XIAO J， WANG H， LIU X， et al. From escort to target， the multidimensional roles and prospects of platelets in tumor immune checkpoint inhibitor therapy［J］. Front Immunol， 2026，17（3）：1764513. doi： 10.3389/fimmu.2026.1764513 .
[7] ROLFES V， IDEL C， PRIES R， et al. PD-L1 is expressed on human platelets and is affected by immune checkpoint therapy［J］. Oncotarget， 2018， 9（44）：27460-27470. doi： 10.18632/oncotarget.25446 .
[8] GAN J， ZHANG X， GUO J. The role of platelets in tumor immune evasion and metastasis： mechanisms and therapeutic implications［J］. Cancer Cell Int， 2025，25（1）：258. doi： 10.1186/s12935-025-03877-w .
[9] TRIVANOVI? D， MOJSILOVI? S， BOGOSAVLJEVI? N， et al. Revealing profile of cancer-educated platelets and their factors to foster immunotherapy development［J］. Transl Oncol， 2024， 40（2）：101871. doi： 10.1016/j.tranon.2023.101871 .
[10] LU Q， YE H， ZHAO J， et al. Surface-Anchored Ticagrelor Gelatin Nanoparticles-Platelets System for Enhanced Anti-PD-L1 Therapy Response and Boosted Chemotherapeutic Efficacy of Nanomedicines［J］. Exploration （Beijing）， 2025，5（3）：20240084. doi： 10.1002/EXP.20240084 .
[11] ZASLAVSKY A B， ADAMS M P， CAO X， et al. Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors［J］. Sci Rep， 2020， 10（1）：19296. doi： 10.1038/s41598-020-76351-4 .
[12] GUO Q， MALLOY M W， ROWETH H G， et al. Platelets upregulate tumor cell programmed death ligand 1 in an epidermal growth factor receptor-dependent manner in vitro［J］. Blood Adv， 2022， 6（20）：5668-5675. doi： 10.1182/bloodadvances .
[13] LI J， LIU J， YANG S， et al. PD-L1 positive platelets mediate resistance to immune checkpoint inhibitors in patients with colorectal cancer［J］. Cell Commun Signal， 2025， 23（1）：29. doi： 10.1186/s12964-025-02034-0 .
[14] XU C， XIA Y， ZHANG B W， et al. Macrophages facilitate tumor cell PD-L1 expression via an IL-1β-centered loop to attenuate immune checkpoint blockade［J］. Med Comm， 2023， 4（2）：e242. doi： 10.1002/mco2.242 .
[15] YI M， NIU M， XU L， et al. Regulation of PD-L1 expression in the tumor microenvironment［J］. Hematol Oncol， 2021， 14（1）：10. doi： 10.1186/s13045-020-01027-5 .
[16] RONG Q X， WANG F， GUO Z X， et al. GM-CSF mediates immune evasion via upregulation of PD-L1 expression in extranodal natural killer/T cell lymphoma［J］. Mol Cancer， 2021， 20（1）：80. doi： 10.1186/s12943-021-01374-y .
[17] LI Z， LIU J， YAN M， et al. Tumor-educated platelets： from molecular mechanisms to liquid biopsy and therapeutic applications［J］. Int J Pharm， 2026， 694：126708. doi： 10.1016/j.ijpharm. 2026.126708 .
[18] MASUBUCHI T， CHEN L， MARCEL N， et al. Functional differences between rodent and human PD-1 linked to evolutionary divergence［J］. Sci Immunol， 2025， 10（103）：6295. doi： 10.1126/sciimmunol.ads6295 .
[19] MAGIERA-MULARZ K， KOCIK J， MUSIELAK B， et al. Human and mouse PD-L1： similar molecular structure， but different druggability profiles［J］. iScience， 2020， 24（1）：101960. doi： 10.1016/j.isci.2020.101960 .
[20] STAICU I. Human versus mouse PD-1［J］. Nat Immunol， 2025， 26（2）：149. doi： 10.1038/s41590-025-02086-x .
[21] TANG M， ZHANG Z， WANG P， et al. Advancements in precision nanomedicine design targeting the anoikis-platelet interface of circulating tumor cells［J］. Acta Pharm Sin B， 2024， 14（8）：3457-3475. doi： 10.1016/j.apsb.2024.04.034 .
[22] SUN Y， LI T， DING L， et al. Platelet-mediated circulating tumor cell evasion from natural killer cell killing through immune checkpoint CD155-TIGIT［J］. Hepatology， 2025， 81（3）：791-807. doi： 10.1097/HEP.0000000000000934 .
[23] MAURER S， KROPP KN， KLEIN G， et al. Platelet-mediated shedding of NKG2D ligands impairs NK cell immune-surveillance of tumor cells［J］. Oncoimmunology， 2017， 7（2）：e1364827. doi： 10.1080/2162402X.2017.1364827 .
[24] CHO M S， LEE H， GONZALEZ-DELGADO R， et al. Platelets Increase the Expression of PD-L1 in Ovarian Cancer［J］. Cancers （Basel）， 2022， 14（10）：2498. doi： 10.3390/cancers14102498 .
[25] SMITH-OLIVER M R， GAUTAM D， PETRARCA G C， et al. Tumor-Associated Platelets Suppress T-Cell Function and Promote Immune Evasion in TNBC via the P-selectin/ P-selectin glycoprotein ligand-1 Pathway［J］. Cancer Res Commun， 2026，6（7）：1640-1655. doi： 10.1158/2767-9764.CRC-26-0187 .
[26] LIU Y， ZHANG Y， DING Y， et al. Platelet-mediated tumor metastasis mechanism and the role of cell adhesion molecules［J］. Crit Rev Oncol Hematol， 2021， 167：103502. doi： 10.1016/j.critrevonc.2021.103502 .
[27] VASILAKI D， BAKOPOULOU A， TSOUKNIDAS A， et al. Biophysical interactions between components of the tumor microenvironment promote metastasis［J］. Biophys Rev， 2021， 13（3）：339-357. doi： 10.1007/s12551-021-00811-y .
[28] RASKOV H， ORHAN A， AGERB?K M ?， et al. The impact of platelets on the metastatic potential of tumour cells［J］. Heliyon， 2024， 10（14）：e34361. doi： 10.1016/j.heliyon.2024.e34361 .
[29] HINTERLEITNER C， STR?HLE J， MALENKE E， et al. Platelet PD-L1 reflects collective intratumoral PD-L1 expression and predicts immunotherapy response in non-small cell lung cancer［J］. Nat Commun， 2021， 12（1）：7005. doi： 10.1038/s41467-021-27303-7 .
[30] COLARUSSO C， FALANGA A， TERLIZZI M， et al. High levels of PD-L1 on platelets of NSCLC patients contributes to the pharmacological activity of Atezolizumab［J］. Biomed Pharmacother， 2023， 168：115709. doi： 10.1016/j.biopha.2023.115709 .
[31] LEE S W， JEONG S， KIM Y J， et al. Enhanced thrombopoiesis supplies PD-L1 to circulating immune cells via the generation of PD-L1-expressing platelets in patients with lung cancer［J］. Immunother Cancer， 2025， 13（2）：e010193. doi： 10.1136/jitc-2024-010193 .
[32] DARGA E P， DOLCE E M， FANG F， et al. PD-L1 expression on circulating tumor cells and platelets in patients with metastatic breast cancer［J］. PLoS One， 2021， 16（11）：e0260124. doi： 10.1371/journal.pone.0260124 .
[33] K?TT J， MATTHES N， BAUER A T， et al. Synergistic effects of anticoagulants and platelet aggregation inhibitors with immune checkpoint inhibitors in cancer therapy： a comprehensive review of preclinical and clinical evidence［J］. Immunother Cancer， 2026 Feb 4；14（2）：e013879. doi： 10.1136/jitc-2025-013879 .
[34] GAO Y， CHEN X， WANG B， et al. Engineering Platelets with PDL1 Antibodies and Iron Oxide Nanoparticles for Postsurgical Cancer Immunotherapy［J］. ACS Appl Bio Mater， 2023， 6（1）：257-266. doi： 10.1021/acsabm.2c00869 .
[35] DA X， MO J， LI Q， et al. Targeted co-delivery of PD-L1 monoclonal antibody and sorafenib to circulating tumor cells via platelet-functionalized nanocarriers［J］. Biochem Biophys Res Commun， 2023， 671：335-342. doi： 10.1016/j.bbrc.2023.05.124 .
[36] WU S， WU Z， LU Z， et al. Selective apoptosis of tumor-associated platelets boosts the anti-metastatic potency of PD-1 blockade therapy［J］. Cell Rep Med， 2025， 6（3）：101984. doi： 10.1016/j.xcrm.2025.101984 .
[37] ZHANG Y， WANG Z J， WANG J， et al. Immunomodulating platelet-mimicking nanoparticles for AIE-based enhanced photodynamic immunotherapy against lung cancer［J］. Materials Today Bio， 2025， 32：101683. doi： 10.1016/j.mtbio.2025.101683 .
[38] LV Y， MA G. Platelet-Based Nanotechnology Improves Cancer Immunotherapy［J］. Eur J Immunol， 2025， 55（7）：e70017. doi： 10.1002/eji.70017 .
[39] GRANICA M， LASKOWSKI G， LINK-LENCZOWSKI P， et al. Modulation of N-glycosylation in the PD-1： PD-L1 axis as a strategy to enhance cancer immunotherapies［J］. Biochim Biophys Acta Rev Cancer， 2025， 1880（2）：189274. doi： 10.1016/j.bbcan.2025.189274 .
[40] WANG X， HUANG Y， LUO T， et al. Rewiring immune evasion in liver metastases： WNT11 as a central node - a mini review［J］. Front Oncol， 2025， 15（3）：1666889. doi： 10.3389/fonc.2025. 1666889 .
[41] NASSER N J， SINDHU K K， NASSER L， et al. Immune Checkpoint Inhibition in Patients with Brain Metastases from Non-Small-Cell Lung Cancer： Emerging Mechanisms and Personalized Clinical Strategies［J］. Int J Mol Sci， 2025， 26（17）：8624. doi： 10.3390/ijms26178624 .
[42] CHEN Y， WOLTER T， GU Z， et al. Engineering platelets as cancer therapeutics［J］. Nat Rev Clin Oncol， 2026， 23（5）：323-340. doi： 10.1038/s41571-026-01122-5 .
[43] WANG Y， OGUNNAIKE E， YANG H， et al. Platelet-engineered CAR-T cells as adjuvant therapy after cancer surgery［J］. Proc Natl Acad Sci U S A， 2025， 122（51）：e2522020122. doi： 10.1073/pnas.2522020122 .
Options
Outlines

/

〈 〉